Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
Open Access
- 18 November 2023
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 8 (1) , 133-146
Abstract
Background The aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States. Methods Eligible adults with newly diagnosed PAH from Optum’s de-identified Clinformatics® Data Mart Database (2016–2021) were assigned to mutually exclusive cohorts based on time between first PAH-related symptom and first PAH diagnosis (i.e., ≤12 months’ delay, >12 to ≤24 months’ delay, >24 months’ delay). All-cause HRU and health care costs per patient per month (PPPM) were assessed during the first year following diagnosis and compared across cohorts using regression analysis adjusted for baseline covariates. Sensitivity analyses were conducted to assess outcomes during all available follow-up post-diagnosis. Results Among 538 patients (mean age: 65.6 years; 60.6% female), 60.8% had ≤12 months’ delay, 23.4% had a delay of >12 to ≤24 months, and 15.8% had >24 months’ delay. Compared with ≤12 months, delays of >12 to ≤24 months and >24 months were associated with increased hospitalizations (incidence rate ratio [95% confidence interval]: 1.40 [1.11–1.71] vs 1.71 [1.29–2.12]) and outpatient visits (1.17 [1.06–1.30] vs 1.26 [1.08–1.41]). Longer delays were also associated with more intensive care unit (ICU) stays and 30-day readmissions. Diagnosis delays translated into excess costs PPPM of US$3986 [1439–6436] for >12 to ≤24 months and US$5366 [2107–8524] for >24 months compared with ≤12 months’ delay; increased hospitalization costs (US$3248 [1108–5135] and US$4048 [1401–6342], respectively) being the driver. Sensitivity analyses yielded similar trends. Conclusions Delayed PAH diagnosis is associated with significant incremental economic burden post-diagnosis, driven by hospitalizations including ICU stays and 30-day readmissions, highlighting the need for increased awareness and a potential benefit of earlier screening.Keywords
Funding Information
- Janssen Scientific Affairs
This publication has 38 references indexed in Scilit:
- Pulmonary Arterial HypertensionJACC, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United StatesJournal of Medical Economics, 2012
- The cost to managed care of managing pulmonary hypertensionJournal of Medical Economics, 2012
- Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured PopulationApplied Health Economics and Health Policy, 2011
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United StatesChest, 2011
- Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United StatesJournal of Medical Economics, 2010
- Pulmonary Arterial HypertensionChest, 2010
- Pulmonary Arterial Hypertension in FranceAmerican Journal of Respiratory and Critical Care Medicine, 2006